There was a significant increase in median survival at all doses compared to controls of saline, cold NNV002, or Pb212Cetuximabb. At the respective doses 70%, 90% and 100% of mice injected with MEC-2 cells were tumor-free 20 weeks post cell injection compared with a median survival of 4.9, 5.4 and 9.3 weeks in the control samples. Similar results were obtained with the Daudi cells.
Presented by: Amal Saidi, PhD, Orano Med, Plano, Texas, United States
Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10) April 1 - April 4, 2019 - Ottawa, ON, Canada